Reading CTKB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTKB free→Reading CTKB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTKB free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-12
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been steady, but the capital stance is capital unfriendly, and risk is elevated. The sector backdrop is a headwind, and compared with sector peers, it is below typical. Peer multiples imply a price about 45% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.96. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.96 CTKB trades at 2× p/s, below its 3× p/s peer median. Our $7.08 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 44% below a flat-multiple fair value, below our forecast of about 12%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.04 → $-0.01 (+75.0% / 30d). 0 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$167.
How much price usually moves either way.
On a bad day, this stock has moved -$577.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,294.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show if revenue growth is slowing. This is key for future performance.
Confirms:Earnings report shows revenue growth below the median for the sector.
Disproves:Earnings report shows revenue growth above the median for the sector.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CTKB yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Senior Vice President, Global Sales and Services — Philippe Busque, Ph.D.: Dr. Busque resigned to pursue another career opportunity.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2021-Q3, 2022-Q1, 2022-Q2, 2022-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CTKB Cytek Biosciences, Inc. | Below typical Show detailsSector percentile: 19 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Cytek aims to meet its 2026 revenue guidance range of $205 million to $212 million.
Cytek is focused on improving its operating income through cost management and efficiency.
Cytek aims to increase its gross profit through strategic initiatives and cost management.
Why it matters: Achieving revenue guidance is key for Cytek's growth strategy. It shows demand and market position.
Confirms:Q2 revenue reported between $205M and $212M.
Disproves:Q2 revenue reported below $205M.
Why it matters: A drop in sector revenue growth could signal broader challenges for Cytek. It may affect market confidence.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains above its median.
Why it matters: Better operating income is key for making more money in the long run. It shows improved cost control.
Confirms:Operating income is better than in Q1.
Disproves:Operating income has dropped or stayed the same since Q1.
Why it matters: The departure of the President may affect sales strategy and execution. This could impact revenue.
Confirms:Sales performance gets better in the next quarter, even with a leadership change.
Disproves:Sales went down after the executive change.
and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.